Search results for "VIRUS DISEASE"

showing 10 items of 1907 documents

The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report

2009

Abstract Hepatitis C virus (HCV) genotypes 4, 5 and 6 represent20% of all HCV cases worldwide. HCV-4 is mainly seen in Egypt, where it represents 90% of all HCV cases. Antischistosomal therapy was the main cause of contamination there, followed by procedures performed by informal providers and traditional healers such as dental care, wound treatment, circumcision, deliveries, excision and scarification. It is also highly prevalent in sub-Saharan Africa and in the Middle East. In Europe, its prevalence has recently increased particularly among intravenous drug users and in immigrants. HCV-5 is mainly found in South Africa, where it represents 40% of all HCV genotypes, but four pockets of HCV…

medicine.medical_specialtyGenotypeHepatitis C virusHepacivirusmedicine.disease_causechemistry.chemical_compoundPharmacotherapyPegylated interferonInternal medicineEpidemiologyPrevalencemedicineHumansHepatologybusiness.industryTransmission (medicine)Ribavirinvirus diseasesHepatitis Cmedicine.diseaseHepatitis CVirologydigestive system diseaseschemistryHCVbusinessViral hepatitismedicine.drugLiver International
researchProduct

Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection

2020

Data on the prevalence of resistance-associated substitutions (RASs) and their implications for treatment with direct-acting antivirals (DAAs) are sparse in European patients with HCV genotype 4. This study investigated RASs before and after DAA failure in different genotype 4 subtypes and evaluated retreatment efficacies. Samples of 195 genotype 4-infected patients were collected in the European Resistance Database and investigated for NS3, NS5A and NS5B RASs. Retreatment efficacies in DAA failure patients were analysed retrospectively. After NS5A inhibitor (NS5Ai) failure, subtype 4r was frequent (30%) compared to DAA-naive patients (5%) and the number of NS5A RASs was significantly highe…

medicine.medical_specialtyGenotypeHepatitis C virusMedizinHCV genotype 4HepacivirusViral Nonstructural Proteinsmedicine.disease_causeGastroenterologyAntiviral AgentsVirus03 medical and health scienceschemistry.chemical_compound0302 clinical medicineResistance-associated substitutionsChronic hepatitisMembrane interactionVirologyInternal medicineGenotypeDrug Resistance ViralmedicineHumansIn patient030212 general & internal medicineTreatment FailureNS5ANS5BRetrospective Studiesddc:616Hepatologybusiness.industryHepatitis C virusvirus diseasesHepatitis C Chronicdigestive system diseasesInfectious DiseaseschemistryRetreatmentDAA failure030211 gastroenterology & hepatologybusiness
researchProduct

Sequential evolution of genotype GII.4 norovirus variants causing gastroenteritis outbreaks from 2001 to 2006 in Eastern Spain.

2008

Noroviruses are the most common cause of outbreaks of viral gastroenteritis worldwide. Norovirus outbreaks were surveyed in Catalonia and the region of Valencia (Eastern Spain) between January 2001 and December 2006 as part of the European Union funded network "Food-borne viruses in Europe". During this time the etiology and epidemiological features of 194 outbreaks of acute non-bacterial gastroenteritis were investigated and norovirus was identified as causing 169 (87.1%) of them. Molecular epidemiology of viral strains was studied by RT-PCR and sequencing part of the RNA polymerase gene in ORF1 from 153 outbreak strains. The most commonly identified norovirus genotype was GII.4 (71.9% of …

medicine.medical_specialtyGenotypevirusesBiologymedicine.disease_causeMicrobiologyDisease OutbreaksEvolution MolecularFecesfluids and secretionsVirologyGenotypeGenetic variationEpidemiologymedicinemedia_common.cataloged_instanceHumansEuropean unionPhylogenymedia_commonCaliciviridae InfectionsMolecular epidemiologyNorovirusvirus diseasesOutbreakGenetic VariationVirologyGastroenteritisInfectious DiseasesSpainNorovirusEtiologySeasonsJournal of medical virology
researchProduct

Association between environmental pollution and prevalence of coronavirus disease 2019 (COVID-19) in Italy

2020

AbstractThe novel coronavirus disease 2019 (COVID-19) has recently been upgraded to a pandemic by the World Health Organization due to the alarming levels of spread and severity. Since several lines of evidence also attest that Lombardy region has an extraordinarily high level of environmental pollution, we aimed to explore the potential epidemiological association between the number of cases of COVID-19 and environmental pollution in Italy. Data on environmental pollution in Italy were retrieved from the 2019 annual report of the organization Legambiente (League for the Ambient). The adjusted correlation between the number of days in which environmental pollutants exceeded established limi…

medicine.medical_specialtyGeographyCoronavirus disease 2019 (COVID-19)Environmental healthEpidemiologyPandemicmedicineEnvironmental pollutionWorld health
researchProduct

Hepatitis B virus in diabetic patients

1980

The presence of HBV markers was determined in 149 serum samples obtained from diabetic patients and was compared with a normal population. Diabetics have the same incidence of HBsAg but significantly higher anti-HBc antibodies. These differences were seen in the group of diabetics on oral hypoglycemic therapy. These results cannot yet be explained.

medicine.medical_specialtyHBsAgEndocrinology Diabetes and MetabolismHbv markersAntibodies Viralmedicine.disease_causeGastroenterologyHepatitis B AntigensEndocrinologyInternal medicineDiabetes mellitusEpidemiologyDiabetes MellitusInternal MedicinemedicineHumansHepatitis B AntibodiesHepatitis B virusbiologybusiness.industryIncidence (epidemiology)virus diseasesGeneral MedicineSerum samplesmedicine.diseasedigestive system diseasesImmunologybiology.proteinAntibodybusinessActa Diabetologica Latina
researchProduct

Knowledge about infection with human papillomavirus: a systematic review.

2007

Abstract Objective. Human papillomavirus (HPV) is a necessary cause of cervical cancer and genital warts. The aim of this systematic literature review was to provide an overview of knowledge about HPV infection among the public, students, patients and health professionals. Method. PubMed searches were performed and the results of studies were reported by age, gender, study population, country, recruitment score and year of study conduct. The recruitment score covered the mode of recruitment, study size and response rate. Results. We included 39 studies published between 1992 and 2006 covering a total of 19,986 participants. The proportion of participants who had heard of HPV varied from 13%…

medicine.medical_specialtyHealth Knowledge Attitudes PracticeEpidemiologyPopulationUterine Cervical NeoplasmsGenital wartsmedicineHumansPapillomavirus VaccinesRisk factoreducationPapillomaviridaeGynecologyCervical cancerResponse rate (survey)education.field_of_studybusiness.industryPapillomavirus InfectionsPublic Health Environmental and Occupational HealthHPV infectionvirus diseasesmedicine.diseaseSystematic reviewCondylomata AcuminataFamily medicinePopulation studyFemalebusinessPreventive medicine
researchProduct

Clinical presentation, disease course and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease – a cohort study…

2021

AbstractAimsPatients with cardiac disease are considered high risk for poor outcomes following hospitalization with COVID-19. The primary aim of this study was to evaluate heterogeneity in associations between various heart disease subtypes and in-hospital mortality.Method and resultsWe used data from the CAPACITY-COVID registry and LEOSS study. Multivariable Poisson regression models were fitted to assess the association between different types of pre-existent heart disease and in-hospital mortality. 16,511 patients with COVID-19 were included (21.1% aged 66 – 75 years; 40.2% female) and 31.5% had a history of heart disease. Patients with heart disease were older, predominantly male and of…

medicine.medical_specialtyHeart diseaseCoronavirus disease 2019 (COVID-19)business.industryDiseasemedicine.diseasesymbols.namesakeHeart failureInternal medicineRelative riskmedicinesymbolsPoisson regressionPresentation (obstetrics)businessCohort study
researchProduct

Direct antiviral agents in hepatitis C virus related liver disease: Don’t count the chickens before they’re hatched

2021

Since molecules with direct-acting antiviral (DAA) became available, the landscape of the treatment of hepatitis C virus (HCV) infection has completely changed. The new drugs are extremely effective in eradicating infection, and treatment is very well tolerated with a duration of 8-12 wk. This review aims to report the outstanding clinical benefits of DAA and to highlight their critical disadvantages, identifying some clinically relevant hot topics. First, do the rates of virological response remain as high when patients with more advanced cirrhosis are considered? Large studies have shown slightly lower but still satisfactory rates of response in these patients. Nevertheless, modified sche…

medicine.medical_specialtyHepatitis B virusHepatitis C virusHepatitis C virus/hepatitis B virus coinfection.HepacivirusHypoglycemiamedicine.disease_causeGastroenterologyAntiviral Agents03 medical and health sciencesLiver diseasechemistry.chemical_compound0302 clinical medicineDiabetes mellitusInternal medicinemedicineAnimalsHumansAdvanced cirrhosisDirect antiviral activityHepatitis B virusbusiness.industryHepatitis C virusCoinfectionIncidence (epidemiology)RibavirinGastroenterologyvirus diseasesMinireviewsGeneral MedicineHepatitis C Chronicmedicine.diseaseHepatitis BHepatitis Cdigestive system diseaseschemistry030220 oncology & carcinogenesisCoinfection030211 gastroenterology & hepatologyNeoplasm Recurrence LocalLiver cancerbusinessLiver cancerChickensWorld Journal of Gastroenterology
researchProduct

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

2005

Background/Aims: Prediction of sustained virological response (SVR) during treatment would allow clinicians to identify patients most likely to benefit from therapy. Methods: Retrospective analysis of data from 1121 adults with chronic hepatitis C treated for 48 weeks with peginterferon alfa-2a (40 KD) 180 mu g/week plus placebo or ribavirin (1000/1200 mg/day), or interferon alfa-2b 3 MIU three times/week plus ribavirin in a randomized, multinational, study. Results: 67% of patients treated with peginterferon alfa-2a (40 KD)/ribavirin with early virological responses (HCV RNA negative or >= 2 log(10) decrease) at week 12 had SVRs at week 72 (HCV RNA 80 % of the planned ribavirin dose. Concl…

medicine.medical_specialtyHepatitis B virusviral hepatitisAlpha interferonPeginterferon-alfaInterferon alpha-2medicine.disease_causeGastroenterologyAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundpredictabilityInternal medicineRibavirinmedicinechronic hepatitis CHumansProbabilityRetrospective StudiesHepatitis B viruspeginterferon alfa-2a (40 KD)treatmentHepatologyDose-Response Relationship Drugbusiness.industryRibavirinvirus diseasesInterferon-alphaHepatitis CHepatitis C ChronicViral Loadmedicine.diseasedigestive system diseasesRecombinant ProteinsTreatment OutcomechemistryImmunologyRNA ViralDrug Therapy Combinationsustained virological responseViral hepatitisbusinessViral loadPeginterferon alfa-2amedicine.drugJournal of hepatology
researchProduct

Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus

2011

Summary Nearly three-quarters of human immunodeficiency virus–hepatitis C virus (HIV-HCV) coinfected patients in France currently need to be cured of their chronic HCV infection. The increase in sustained virological response rates obtained with the recently available HCV protease inhibitors in treatment-naive genotype-1 patients has generated considerable hope in these co-infected patients. However, several particularities (such as a higher baseline HCV load, more advanced liver fibrosis, frequent co-morbidities, and the risk of toxicity and drug–drug interactions) have not allowed the direct extrapolation of the results observed in HCV-monoinfected patients to patients with HIV-HCV co-inf…

medicine.medical_specialtyHepatitis C virusHuman immunodeficiency virus (HIV)HIV InfectionsContext (language use)medicine.disease_causeAntiviral AgentsViruschemistry.chemical_compoundPegylated interferonFibrosismedicineHumansIntensive care medicineHepatologybusiness.industryRibavirinGastroenterologyvirus diseasesHepatitis C Chronicmedicine.diseasechemistryImmunologyToxicitybusinessAlgorithmsmedicine.drugClinics and Research in Hepatology and Gastroenterology
researchProduct